Abstract
MicroRNAs (miRNAs), which are small non-coding RNA molecules that post-transcriptionally regulate the expression of target genes, control the vast majority of cellular events, including proliferation, differentiation, survival, senescence, autophagy, metabolism and genome stability. Even slight alterations in miRNA expression levels may induce the development of pathological states, including cancer. Several studies have already demonstrated the importance of miRNAs in the regulation of melanocytes. Upregulation of oncogenic miRNAs (oncomiRs), mainly by amplification and translocation of miRNA genes, and downregulation of oncosuppressor miRNAs (anti-oncomiRs) by deletion and other mutations, promoter methylation and abnormal processing contributes to melanoma initiation and progression. At each phase of melanoma progression, tumor cells exhibit distinct profiles of miRNA expression, as compared with normal melanocytes. Moreover, as miRNAs are stable molecules that can be identified in bodily fluids, such as blood and saliva, they can serve as potent non-invasive prognostic markers of disease progression and response to therapy. This review summarizes recent findings regarding miRNA-mediated control of melanocytes and melanoma development, and presents miRNAs as prognostic markers for this disease.
Keywords: Melanocyte, melanogenesis, melanoma, oncomiR, anti-oncomiR, prognostic marker.
Current Medicinal Chemistry
Title:miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Volume: 23 Issue: 28
Author(s): Michal Wozniak, Aleksandra Mielczarek and Malgorzata Czyz
Affiliation:
Keywords: Melanocyte, melanogenesis, melanoma, oncomiR, anti-oncomiR, prognostic marker.
Abstract: MicroRNAs (miRNAs), which are small non-coding RNA molecules that post-transcriptionally regulate the expression of target genes, control the vast majority of cellular events, including proliferation, differentiation, survival, senescence, autophagy, metabolism and genome stability. Even slight alterations in miRNA expression levels may induce the development of pathological states, including cancer. Several studies have already demonstrated the importance of miRNAs in the regulation of melanocytes. Upregulation of oncogenic miRNAs (oncomiRs), mainly by amplification and translocation of miRNA genes, and downregulation of oncosuppressor miRNAs (anti-oncomiRs) by deletion and other mutations, promoter methylation and abnormal processing contributes to melanoma initiation and progression. At each phase of melanoma progression, tumor cells exhibit distinct profiles of miRNA expression, as compared with normal melanocytes. Moreover, as miRNAs are stable molecules that can be identified in bodily fluids, such as blood and saliva, they can serve as potent non-invasive prognostic markers of disease progression and response to therapy. This review summarizes recent findings regarding miRNA-mediated control of melanocytes and melanoma development, and presents miRNAs as prognostic markers for this disease.
Export Options
About this article
Cite this article as:
Wozniak Michal, Mielczarek Aleksandra and Czyz Malgorzata, miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential, Current Medicinal Chemistry 2016; 23 (28) . https://dx.doi.org/10.2174/1389557516666160831164544
DOI https://dx.doi.org/10.2174/1389557516666160831164544 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Outcome-Dependent Global Similarity Analysis of Imbalanced Core Signaling Pathways in Ischemic Mouse Hippocampus
CNS & Neurological Disorders - Drug Targets TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews Cancer and Treatment Modalities
Current Cancer Therapy Reviews Evidence that Bergapten, Independently of its Photoactivation, Enhances p53 Gene Expression and Induces Apoptosis in Human Breast Cancer Cells
Current Cancer Drug Targets Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Current Molecular Medicine Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary Approach
Current Radiopharmaceuticals Editorial [ Hot Topic:siRNA Based Approaches in Medicinal Chemistry and Drug Discovery (Guest Editor: Raymond M. Schiffelers )]
Current Topics in Medicinal Chemistry Females Live Longer than Males: Role of Oxidative Stress
Current Pharmaceutical Design Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy
Current Nanoscience G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets